Related Experiment Videos
Role of subcutaneous apomorphine in parkinsonian voiding dysfunction
T J Christmas1, P A Kempster, C R Chapple
1Department of Urology, Middlesex Hospital, London.
Lancet (London, England)
|December 24, 1988
Summary
Subcutaneous apomorphine improved voiding efficiency in Parkinson's disease patients with urinary symptoms. This dopamine agonist enhanced flow rates and reduced residual urine, suggesting potential for assessment and treatment.
Area of Science:
- Neurology
- Urology
- Pharmacology
Background:
- Parkinson's disease (PD) frequently causes urinary symptoms.
- Voiding dysfunction in PD impacts patient quality of life.
- Dopamine pathways are implicated in bladder control.
Purpose of the Study:
- To assess the effect of apomorphine on urodynamic parameters in Parkinson's disease patients.
- To evaluate apomorphine's potential in managing urinary dysfunction in PD.
- To investigate apomorphine's impact on voiding efficiency and detrusor activity.
Main Methods:
- Urodynamic assessments were performed before and after subcutaneous apomorphine administration.
- Ten patients with Parkinson's disease and urinary symptoms were included.
- Apomorphine, a dopamine receptor agonist, was administered subcutaneously.
Main Results:
- Voiding efficiency improved post-apomorphine injection.
- Nine patients showed increased mean and maximum flow rates.
- Six patients experienced a reduction in post-micturition residual volume.
Conclusions:
- Subcutaneous apomorphine demonstrates potential utility in assessing and treating voiding dysfunction in Parkinson's disease.
- Apomorphine may offer a therapeutic option for urinary symptoms associated with PD.
- Further research is warranted to explore detrusor behavior variability with apomorphine treatment.